DE60039151D1 - Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen - Google Patents

Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen

Info

Publication number
DE60039151D1
DE60039151D1 DE60039151T DE60039151T DE60039151D1 DE 60039151 D1 DE60039151 D1 DE 60039151D1 DE 60039151 T DE60039151 T DE 60039151T DE 60039151 T DE60039151 T DE 60039151T DE 60039151 D1 DE60039151 D1 DE 60039151D1
Authority
DE
Germany
Prior art keywords
cells
cell
antibody
sign
clumping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039151T
Other languages
German (de)
English (en)
Inventor
Carl Gustav Figdor
Teunis Bernard Geijtenbeek
Kooyk Yvette Van
Ruurd Torensma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Original Assignee
Radboud Universiteit Nijmegen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radboud Universiteit Nijmegen filed Critical Radboud Universiteit Nijmegen
Application granted granted Critical
Publication of DE60039151D1 publication Critical patent/DE60039151D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
DE60039151T 1999-04-19 2000-04-19 Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen Expired - Lifetime DE60039151D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19990201204 EP1046651A1 (en) 1999-04-19 1999-04-19 Composition and method for modulating dendritic cell-T interaction
US17692400P 2000-01-20 2000-01-20
PCT/NL2000/000253 WO2000063251A1 (en) 1999-04-19 2000-04-19 Composition and method for modulating dendritic cell-t cell interaction

Publications (1)

Publication Number Publication Date
DE60039151D1 true DE60039151D1 (de) 2008-07-24

Family

ID=8240111

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60039151T Expired - Lifetime DE60039151D1 (de) 1999-04-19 2000-04-19 Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen
DE60044621T Expired - Lifetime DE60044621D1 (de) 1999-04-19 2000-04-19 Zusammensetzungen und Verfahren zur Modulierung der Interaktion zwischen dendritischer und T-Zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60044621T Expired - Lifetime DE60044621D1 (de) 1999-04-19 2000-04-19 Zusammensetzungen und Verfahren zur Modulierung der Interaktion zwischen dendritischer und T-Zellen

Country Status (13)

Country Link
US (4) US7148329B1 (enExample)
EP (3) EP1046651A1 (enExample)
JP (2) JP4989820B2 (enExample)
KR (3) KR100952883B1 (enExample)
AT (2) ATE472558T1 (enExample)
AU (1) AU776317B2 (enExample)
CA (1) CA2330231C (enExample)
DE (2) DE60039151D1 (enExample)
DK (2) DK1516881T3 (enExample)
ES (2) ES2307502T3 (enExample)
NZ (1) NZ508723A (enExample)
PT (2) PT1516881E (enExample)
WO (1) WO2000063251A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US6515124B2 (en) * 2000-02-09 2003-02-04 Hoffman-La Roche Inc. Dehydroamino acids
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
KR100643818B1 (ko) * 2000-05-08 2006-11-10 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
EP1339830A2 (en) * 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
ES2197826B1 (es) * 2002-06-21 2005-04-01 Consejo Superior De Investigaciones Cientificas Compuesto terapeutico frente a la infeccion por leishmania y su uso.
US7541032B2 (en) * 2002-09-20 2009-06-02 Stichting Katholieke Universiteit Antigen uptake receptor for Candida albicans on dendritic cells
US7691591B2 (en) * 2002-09-20 2010-04-06 Stichting Katholieke Universiteit Methods of identifying and isolating cells expressing DC-sign
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
BR0315975A (pt) * 2002-11-05 2005-09-20 Pasteur Institut Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
EP1594533B1 (en) 2003-01-31 2012-04-11 Celldex Research Corporation Antibody vaccine conjugates and uses therefor
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
AU2011211337B2 (en) * 2003-10-16 2014-10-02 Cancure Limited Immunomodulating compositions and uses therefor
EP2591786B1 (en) * 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
EP1699487A4 (en) * 2003-12-15 2009-07-08 Alexion Pharma Inc NEW ANTI-DC-SIGN ANTIBODIES
EP1761248B1 (en) 2004-03-19 2012-05-23 Rodos BioTarget GmbH Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
DK1765294T3 (da) * 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
EP1758558B1 (en) * 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
FR2895262B1 (fr) * 2005-12-22 2009-07-17 Lab Francais Du Fractionnement Inhibition de la reponse immunitaire anti-fviii
AT503387B1 (de) * 2006-03-27 2008-05-15 Univ Wien Pharmazeutische zusammensetzung zur vorbeugung von infektionen
SG173337A1 (en) 2006-07-21 2011-08-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
BRPI0807160A2 (pt) 2007-02-02 2018-09-25 Baylor Res Institute vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
ES2536900T3 (es) * 2007-02-02 2015-05-29 Baylor Research Institute Antígenos multivariables en complejo con anticuerpo monoclonal humanizado de dirección
BRPI0815848A2 (pt) 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
EP2207798A2 (en) 2007-10-29 2010-07-21 Virginia Tech Intellectual Properties, Inc. Porcine dc-sign, icam-3 and lsectin and uses thereof
BRPI0820270A2 (pt) 2007-11-07 2015-06-16 Celldex Therapeutics Inc Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
WO2011011584A1 (en) 2009-07-24 2011-01-27 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
WO2011055550A1 (ja) * 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
JP5690132B2 (ja) 2010-06-17 2015-03-25 株式会社マーレ フィルターシステムズ エンジンの換気システム
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
EP2831095B1 (en) 2012-03-30 2018-11-28 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
EP3549605A1 (en) * 2012-04-04 2019-10-09 Vaxform LLC Adjuvant system for oral vaccine administration
EP2897641B1 (en) * 2012-09-18 2018-07-18 University of Washington through its Center for Commercialization Compositions and methods for antigen targeting to cd180
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
US10688178B2 (en) 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
CN108210503A (zh) * 2016-12-10 2018-06-29 高尚先 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US891992A (en) 1907-06-27 1908-06-30 Henry Hess Method of forming conically-shaped ends upon rollers and other objects.
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
IE922308A1 (en) * 1991-07-16 1993-01-27 Bristol Myers Squibb Co Inhibition of non-cd4 mediated hiv infection
WO1995003234A1 (en) 1993-07-22 1995-02-02 Precision Valve Corporation Multi-directional actuation overcap
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU2670995A (en) 1994-05-26 1995-12-21 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US5548275A (en) * 1995-01-23 1996-08-20 Shambayati; Ali Alarm system for enclosing and protecting an area
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
WO1996023882A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US5871964A (en) * 1996-07-15 1999-02-16 Incyte Pharmaceuticals, Inc. Human C-type lectin
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
WO1998049306A1 (en) * 1997-04-29 1998-11-05 Incyte Pharmaceuticals, Inc. Human c-type lectin
EP0984984A2 (en) * 1997-06-03 2000-03-15 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US6273443B1 (en) * 1998-06-01 2001-08-14 Sunrise Medical Hhg Inc. Universal elevating leg rest assembly
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
IL147902A0 (en) * 1999-08-12 2002-08-14 Agensys Inc C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
EP1339830A2 (en) 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US20030232745A1 (en) 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) * 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
EP1542354B1 (en) * 2003-12-09 2021-02-03 Synergy Microwave Corporation Integrated ultra low noise microwave wideband push-push vco

Also Published As

Publication number Publication date
EP1046651A1 (en) 2000-10-25
KR20080098678A (ko) 2008-11-11
HK1036285A1 (en) 2001-12-28
JP5363432B2 (ja) 2013-12-11
AU776317B2 (en) 2004-09-02
US8105599B2 (en) 2012-01-31
KR100952883B1 (ko) 2010-04-16
US20050118168A1 (en) 2005-06-02
JP2003502283A (ja) 2003-01-21
EP1516881B1 (en) 2010-06-30
ES2307502T3 (es) 2008-12-01
JP4989820B2 (ja) 2012-08-01
ATE398140T1 (de) 2008-07-15
EP1516881A2 (en) 2005-03-23
WO2000063251A1 (en) 2000-10-26
ATE472558T1 (de) 2010-07-15
NZ508723A (en) 2003-12-19
EP1516881A3 (en) 2005-08-31
PT1086137E (pt) 2008-09-09
CA2330231A1 (en) 2000-10-26
DK1086137T3 (da) 2008-10-27
EP1086137B1 (en) 2008-06-11
DK1516881T3 (da) 2010-09-27
ES2346877T3 (es) 2010-10-21
KR20010071530A (ko) 2001-07-28
CA2330231C (en) 2013-07-16
DE60044621D1 (de) 2010-08-12
EP1086137A1 (en) 2001-03-28
JP2010285450A (ja) 2010-12-24
KR20070094990A (ko) 2007-09-27
PT1516881E (pt) 2010-08-25
AU4152600A (en) 2000-11-02
US20080160041A1 (en) 2008-07-03
US20050220804A1 (en) 2005-10-06
KR100923340B1 (ko) 2009-10-22
US7148329B1 (en) 2006-12-12
US7285642B2 (en) 2007-10-23
US8058400B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
ATE398140T1 (de) Zusammensetzung und verfahren zur modulierung der dendritischer-zell - t-zell wechselwirkungen
JP6998763B2 (ja) Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体
AU2016263198C1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
TWI691596B (zh) 嵌合抗原和ｔ細胞受體及使用方法
US20190144556A1 (en) Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
MX2012012833A (es) Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
CN113527521A (zh) 一种抗b7h3嵌合抗原受体及其应用
KR20180099641A (ko) 세포의 배양 방법 및 이를 위한 키트와 장치
WO2017197347A1 (en) METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
JP2021098708A (ja) シンデカン−２のモジュレーターとその使用
CN106999556A (zh) 细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗
WO2021241729A1 (ja) 抗ｃｄ７３抗体およびその用途
Tsuda et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis
US20230181642A1 (en) Immune cells with enhanced function
Bezverbnaya et al. Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma
US12221480B2 (en) Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof
CA3160609A1 (en) Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof
US20210108176A1 (en) Transduction and expansion of cells
IL311901A (en) Multiple specific binding agents against PD-L1 and CD137 in combination therapy
CN119215188B (zh) 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途
JPWO2020219843A5 (enExample)
WO2023171009A1 (ja) Ｅｖａ１タンパク質に結合する、ヒト化抗体又はその機能的断片、抗体薬物複合体及びキメラ抗原受容体
Xie et al. cells inhibit the growth of solid tumors
CN118272315A (zh) 一种通用型car-t细胞及其构建方法和应用
NZ763587A (en) Methods, kits and apparatus for expanding a population of cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition